Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: A report using RTOG 90-06

International Journal of Radiation Oncology Biology Physics

Volumn 40, Issue 1, 1998, Pages 51-55

  Scott, Charles B ^a   Scarantino, Charles ^b   Urtasun, Raul ^c   Movsas, Benjamin ^d   Jones, Christopher U ^e   Simpson, Joseph R ^f   Fischbach, A Jennifer ^g   Curran Jr , Walter J ^h  

^a RADIATION THERAPY ONCOLOGY GROUP   (United States)

^b Rex Cancer Center   (United States)

^c Cross Cancer Center   (Canada)

^d FOX CHASE CANCER CENTER   (United States)

^e Radiological Associates of Sacramento Medical Group Inc   (United States)

^f WASHINGTON UNIVERSITY   (United States)

^g LDS HOSPITAL   (United States)

^h THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Glioma; Recursive partitioning analysis; Survival; Validation

Indexed keywords

CARMUSTINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; PHASE 3 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; RELIABILITY; SURVIVAL;

DOSE FRACTIONATION; GLIOMA; HUMANS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS;

EID: 0031964497     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(97)00485-9     Document Type: Article

References (20)

1. Brookmeyer R., Crowley J. A. Confidence interval for the median survival time. Biometrics. 38:1982;29-41.
2. Cox D. R. Regression models and life tables. J. R. Stat. Soc. Series B. 34:1972;187-229.
3. Curran W. J. Jr, Scott C. B., Horton J., Nelson J. S., Weinstein A. S., Fischbach A. J., Chang C. H., Rotman M., Asbell S. O., Krisch R. E., Nelson D. F. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J. Natl. Cancer. Inst. 85:1993;704-710.
4. Curran W. J. Jr, Scott C. B., Nelson J. S., Weinstein A. S., Phillips T. L., Murray K., Fischbach A. J., Yakar D., Schwade J. G., Powlis W. D., Nelson D. F. A randomized trial of accelerated hyperfractionated radiation therapy and bis-chlorethyl nitrosourea for malignant glioma. A preliminary report of Radiation Therapy Oncology Group 83-02. Cancer. 70:1992;2909-2917.
5. Deutsch M., Green S. B., Strike T. A., Burger P. C., Robertson J. T., Selker R. G., Shapiro W. R., Mealey J. Jr, Ransohoff J. II, Paoletti P., Smith K. R. Jr, Odom G. L., Hunt W. E., Young B., Alexander E. Jr, Walker M. D., Pistenmaa D. A. Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma. Int. J. Radiat. Oncol. Biol. Phys. 16:1989;1389-1396.
6. Dinapoli R. P., Brown L. D., Arusell R. M., Earle J. D., O'Fallon J. R., Buckner J. C., Sheithauer B. W., Krook J. E., Tschetter L. K., Maier J. A., Pfeifle D. M., Gesme D. H. Jr. Phase III comparative evaluation of PCNU and carmustine combined with radiation therapy for high-grade glioma. J. Clin. Oncol. 11:1993;1316-1321.
7. Kaplan E. L., Meier P. Nonparametric estimation from incomplete observations. J. Amer. Stat. Assoc. 53:1958;457-481.
8. Kirby S., Brothers M., Irish W., Florell R., Macdonald D., Schold S. C., Cairncross G. Evaluating glioma therapies Modeling treatments and predicting outcomes . J. Natl. Cancer Inst. 87:1995;1884-1888.
9. Korn E. L., Simon R. Measures of explained variation for survival data. Stat. Med. 9:1990;487-503.
10. Kristiansen K., Hagen S., Kollevold T., Torvik A., Holme I., Nesbakken R., Hatlevoll R., Lingren M., Brun A., Lingren S., Notter G., Andersen A. P., Elgen K. Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potential of bleomycin on survival time A prospective multicenter trial of the Scandinavian Glioblastoma Study Group . Cancer. 47:1981;649-652.
11. Larson, D. A.; Gutin, P. H.; McDermott, M.; Lamborn, K.; Sneed, P. K.; Wara, W. M.; Flickinger, J. C.; Kondziolka, D.; Lunsford, L. D.; Hudgins, W. R.; Friehs, G. M.; Haselsberger, K.; Leber, K.; Pendl, G.; Chung, S. S.; Coffey, R. J.; Dinapoli, R., Shaw, E. G.; Vermeulen, S.; Young, R. F.; Hirato, M.; Inoue, H. K.; Ohye, C.; Shibazaki, T. Gamma knife for glioma: Selection factors and survival. Int. J. Radiat. Oncol. Biol. Phys. In press.
12. Murray K. J., Nelson D. F., Scott C., Fischbach A. J., Porter A., Farnan N., Curran W. J. Jr. Quality adjusted survival analysis of malignant glioma patients treated with twice-daily radiation (RT) and carmustine A report of Radiation Therapy Oncology Group (RTOG) 83-02 . Int. J. Radiat. Oncol. Biol. Phys. 31:1995;453-459.
13. Nelson, D. F.; Curran, W. J. Jr.; Scott, C.; Nelson, J. S.; Weinstein, A. S.; Ahmad, K.; Constine, L. S.; Murray, K.; Powlis, W. D.; Mohuiddin, M.; Fischbach, J. Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma - possible advantage observed at 72.0 Gy in 1.2 Gy b.i.d. fractions: Report of the Radiation Therapy Oncology Group Protocol 8302. Int. J. Radiat. Oncol. Biol. Phys. 25:193-207; 1993.
14. Nelson D. F., Diener-West M., Weinstein A. S., Schoenfeld D., Nelson J. S., Sause W. T., Chang C. H., Goodman R., Carabell S. A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery Final report of an RTOG study . Int. J. Radiat. Oncol. Biol. Phys. 12:1986;1793-1800.
15. Payne D. G., Simpson W. J., Keen C., Platts M. E. Malignant astrocytoma Hyperfractionated and standard radiotherapy with chemotherapy in a randomized prospective clinical trial . Cancer. 50:1982;2301-2306.
16. Prentice R. L., Marek P. A qualitative discrepancy between censored data rank tests. Biometrics. 35:1979;861-867.
17. Perry, J. R.; DeAngelis, L. M.; Schold, S. C., Jr.; Burger, P. C.; Brem, H.; Brown, M. T.; Curran, W. J.; Scott, C. B.; Prados, M. D.; Kaplan, R.; Cairncross, J. G. Challenges in the design and conduct of phase III brain tumor therapy trials. J. Neurol. (In press).
18. Sarkaria J. N., Mehta M. P., Loeffler J. S., Buatti J. M., Chappell R. J., Levin A. B., Alexander E. III, Friedman W. A., Kinsella T. J. Radiosurgery in the initial management of malignant gliomas Survival comparison with the RTOG recursive paritioning analysis . Int. J. Radiat. Oncol. Biol. Phys. 32:1995;931-941.
19. Shapiro W. R., Green S. B., Burger P. C., Mahaley M. S., Selker R. G., Van Gilder J. C., Robertson J. T., Ransohoff J., Mealey J. Jr, Strike T. A., Pistenmaa D. A. Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma Brain Tumor Cooperative Group trial 8001 . J. Neurosurg. 71:1989;1-9.
20. Walker M. D., Green S. B., Byar D. P., Alexander E. Jr, Batzdorf U., Brooks W. H., Hunt W. E., MacCarty C. S., Mahaley M. S., Mealey J. Jr, Owens G., Ransohoff J., Robertson J. T., Shapiro W. R., Smith K. R. Jr, Wilson C. B., Strike T. A. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N. Engl. J. Med. 303:1980;1323-1329.